



Regina F. Gandour-Edwards, M.D., M.H.S., M.S.

Clinical Interests	Regina Gandour-Edwards' expertise is in general surgical pathology with an emphasis on urologic cancers and head/neck cancers. She is leader of the Cancer Center Biorepository and has recently published studies relative to patient consenting issues and specimen quality in breast cancer. She has a joint appointment in Urology and has several years of collaboration with the prostate cancer program involving mechanisms of prostate cancer initiation and progression.
Title	Professor Professor, Department of Pathology and Laboratory Medicine
Specialty	Surgical Pathology, Cancer , Pathology and Laboratory Medicine, Pathology - Anatomic
Department	Pathology and Laboratory Medicine
Division	Anatomic Pathology
Center/Program Affiliation	UC Davis Comprehensive Cancer Center
Address/Phone	Pathology Building, 4400 V St. Sacramento, CA 95817 Phone: 916-734-2525
Additional Phone	Phone: 916-734-2571 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., UC Davis School of Medicine, Sacramento, California, 1985 B.S., Georgetown University, Washington, District of Columbia, 1969
Residency	University of California, Davis Medical Center, Sacramento, California, 1985-90
Board Certifications	American Board of Pathology, Anatomic and Clinical Pathology, 1990
Professional Memberships	College of American Pathologists International Society for Biological and Environmental Repositories International Society of Urologic Pathology United States and Canadian Academy of Pathology
Select Recent Publications	Bekele W, Gerscovich EO, Naderi S, Bishop J, Gandour-Edwards RF, McGahan JP. Sonography of an epidermoid inclusion cyst of the thyroid gland. <i>J Ultrasound Med.</i> 2012 Jan;31(1):128-9. Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in



Regina F. Gandour-Edwards, M.D., M.H.S., M.S.

combination with vinorelbine in solid tumors. *Ann Oncol*. 2012 Apr;23(4):1023-9. Epub 2011 Jul 21.

Bailey TL, Fung MA, Gandour-Edwards R, Ellis WG, Schrot RJ. Clinical emergence of neurometastatic merkel cell carcinoma: a surgical case series and literature review. *J Neurooncol*. 2011 Mar;102(1):147-55. Epub 2010 Jul 29.

Li B, Bobinski M, Gandour-Edwards R, Farwell DG, Chen AM. Overstaging of cartilage invasion by multidetector CT scan for laryngeal cancer and its potential effect on the use of organ preservation with chemoradiation. *Br J Radiol*. 2011 Jan;84(997):64-9. Epub 2010 Sep 21.

Gerscovich EO, Naderi S, Gandour-Edwards RF. Serous papillary carcinoma of the tunica vaginalis testis. *J Ultrasound Med*. 2011 Mar;30(3):418-20.

Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW. Dual blockade of PKA and NF- β inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. *Horm Cancer*. 2011 Aug;2(4):224-38.

Kim RH, Coates JM, Bowles TL, McNerney G, Sutcliffe J, Jung JU, Gandour-Edwards B., Chuang F, Bold RJ, Kung HJ. Arginine deaminase as a novel therapy for prostate cancer induces autophagy and caspase independent apoptosis. *Cancer Research* 69:700-708. 2009 (PMID: 19147587)

Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE. A Phase I Study of Gemcitabine and Capecitabine in Patients with Advanced Renal Cell Cancer: Southwest Oncology Group Study S0312. *Am J Clin Oncol*. 2009 May 29. [Epub ahead of print] (PMID: 19487915)

Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. *Oncogene* 27:499-505. 2008 (PMID: 17653089)

You Z, Dong Y, Kong X, Beckett L, Gandour-Edwards R, Melamed J. Midkine is a NF- κ B inducible gene that supports prostate cancer cell survival. *BMC Medical Genomics* 1:6-10. 2008 (PMID: 18275606)

Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen independent growth of prostate cancer cells. *The Prostate* 68:1816-1826. 2008 (PMID: 18780293)

Gandour-Edwards R, Taylor S, Beckett LA. Tumor grade predicts tumor proportion in fresh frozen tissue samples for breast cancer research. *Cell Preservation Technology* 6:1-4. 2008

Gandour-Edwards R, Nguyen H, Castillo M, Soares S. Patient consent: a major obstacle in tissue banking? Perspectives from the University of California Davis. *Cell Preservation Technology* 5:151-



Regina F. Gandour-Edwards, M.D., M.H.S., M.S.

154. 2007

Mudryj M, Reay E, Beckett B, Dandekar S, deVere White RW, Gandour-Edwards, R. Novel p53/p130 axis in bladder carcinoma. *Urology* 70:608-612. 2007 (PMID: 17905135)

Shi XB, Xue L, Tepper CG, Gandour-Edwards R, Ghosh P, Kung HJ, deVere White R. The Oncogenic Potential of a Prostate Cancer-Derived Androgen Receptor Mutant. *Prostate* 2007 May 1; 67(6):591-602. (PMID: 17262801)

Vinall R, Shi XB, Tepper CG, Xue L, Gandour-Edwards R, deVere White RW. The R273H p53 mutation can facilitate the androgen independent growth of LNCaP by a mechanism that involves relaxin H2 and its cognate receptor LGR7. *Oncogene* 30:2082-93. 2006 (PMID: 16434975)

You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, deVere White RW, Reddi AH. Interleukin-17 receptor-like (IL-17RL) gene has anti-apoptotic function associated with androgen independent growth of prostate cancer. *Cancer Res* 1:175-183. 2006 (PMID: 16397230)

© 2017 UC Regents